Mr. John Paulson reports

BAUSCH HEALTH ANNOUNCES BOARD REFRESHMENT

As part of Bausch Health Companies Inc.'s continuing commitment to board refreshment and board diversity, it has nominated two independent and diverse candidates to stand for election to its board of directors at the company's 2024 annual meeting of shareholders: Christian A. Garcia, former executive vice-president and chief financial officer of BrandSafway Industries LLC, and Frank D. Lee, chief executive officer of Pacira Biosciences Inc.

In addition, Russel C. Robertson and Thomas W. Ross will be retiring from the board and will not stand for re-election at the company's 2024 annual meeting. They will, however, continue to serve on the board of Bausch + Lomb Corp. Mr. Robertson and Mr. Ross have served as members of the board since 2016. To fill the resulting committee vacancies, subject to the election of Mr. Garcia and Mr. Lee to the board, the company expects that Mr. Garcia will serve as the audit and risk committee chair and Mr. Lee will serve on the talent and compensation committee. Mr. Lee is also expected to serve on the science and technology committee.

"The nomination of these two new independent directors demonstrates Bausch Health's ongoing commitment to refreshment, excellence and board diversity," John A. Paulson, chairperson of the Bausch Health board, said. "Additionally, I want to thank Russ and Tom, two long-term, valued members of our board, who helped navigate the company through periods of significant change. Their service to the company has been greatly appreciated."

Bausch Health's 2024 annual meeting has not yet been scheduled. Additional information regarding Mr. Garcia and Mr. Lee, as well as the company's other director nominees, will be included in the company's proxy statement for its 2024 annual meeting, when available.

About Bausch Health Companies Inc.

Bausch Health Companies is a global diversified pharmaceutical company enriching lives through its relentless drive to deliver better health outcomes. It develops, manufactures and markets a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals and eye health, through its controlling interest in Bausch + Lomb. Bausch Health's ambition is to be a globally integrated health care company, trusted and valued by patients, health care professionals, employees and investors.

We seek Safe Harbor.